Ageev F T, Ataullakhanova D M, Sazonova L N, Mareev V Iu, Shugushev Kh Kh
Ter Arkh. 1985;57(12):52-8.
Daily monitoring of the ECG, catheterization of the pulmonary artery, tetrapolar chest rheography, occlusion plethysmography and polarography were employed to study the antiarrhythmic efficacy and the effects on the central and peripheral circulation of the new antiarrhythmic etmozine and etacyzine. Twenty-two patients with a frequent chronic ventricular premature heart beat (PHB) and clinically marked circulatory failure (CF) were entered into the study. Intake of etmozine (600 to 800 mg daily) and etacyzine (100 to 300 mg daily) over 5 to 6 days exerted a positive antiarrhythmic effect in 52.6 and 83.3% of the patients, respectively. Etmozine did not produce any adverse hemodynamic action, whereas etacyzine brought about an insignificant increase in the stroke and minute volumes of the heart (12.3 and 9.8%, respectively). However, the lack of an increase in the heart rate (HR), diastolic pressure in the pulmonary artery and regional vascular resistance (RVR), and no significant rise of the preload (systolic pressure in the right atrium) and afterload (elevation of the mean arterial blood pressure and RVR) attest to the fact that etacyzine has a negligible adverse hemodynamic action in CF patients. Intravenous injection of etmozine does not elicit any changes in the RVR or in the venous tone. Meanwhile intravenous injection of etacyzine leads to a significant reduction in the RVR (23.3%). The treatment with both etmozine and etacyzine given in courses promotes the improvement of the microcirculation and tissue oxygen metabolism in patients presenting with CF. More pronounced positive shifts in the microcirculation were achieved with etacyzine. Apparently, this bears on a more demonstrable arteriolodilatation effect of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
采用每日心电图监测、肺动脉插管、四极胸阻抗图、肢体容积描记法和极谱法,研究新型抗心律失常药乙吗噻嗪和乙胺噻嗪的抗心律失常疗效及其对中枢和外周循环的影响。22例频发慢性室性早搏且有明显临床循环衰竭的患者纳入本研究。5至6天内服用乙吗噻嗪(每日600至800毫克)和乙胺噻嗪(每日100至300毫克),分别使52.6%和83.3%的患者产生了积极的抗心律失常作用。乙吗噻嗪未产生任何不良血流动力学作用,而乙胺噻嗪使心脏的每搏输出量和每分钟心输出量略有增加(分别为12.3%和9.8%)。然而,心率、肺动脉舒张压和局部血管阻力未增加,前负荷(右心房收缩压)和后负荷(平均动脉血压和局部血管阻力升高)也无显著升高,这证明乙胺噻嗪对循环衰竭患者的不良血流动力学作用可忽略不计。静脉注射乙吗噻嗪不会引起局部血管阻力或静脉张力的任何变化。同时,静脉注射乙胺噻嗪会导致局部血管阻力显著降低(23.3%)。乙吗噻嗪和乙胺噻嗪的疗程治疗均能促进循环衰竭患者微循环和组织氧代谢的改善。乙胺噻嗪使微循环出现更明显的积极变化。显然,这与该药更明显的小动脉扩张作用有关。(摘要截短于250字)